68Ga-PSMA-PET/CT-basierte Strahlentherapie beim lokal rezidivierten und oligometastasierten Prostatakarzinom: Frühe Effektivität nach Primärtherapie

Translated title of the contribution: 68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy

Christoph Henkenberens, Christoph A. von Klot, Tobias L. Ross, Frank M. Bengel, Hans Jürgen Wester, Axel S. Merseburger, Jens Vogel-Claussen, Hans Christiansen, Thorsten Derlin

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: The goal of this work was to evaluate the early efficacy of 68Ga-PSMA ligand PET/CT imaging for radiotherapy of locally recurrent and/or oligometastatic prostate cancer. Patients and methods: A total of 29 patients with biochemical recurrence received a 68Ga-PSMA ligand PET/CT for restaging of disease, followed by 3D conformal radiotherapy of metastases or intensity-modulated radiation therapy of the prostate bed. Prostate-specific antigen (PSA) levels and imaging procedures served as the reference standard to assess the treatment efficacy. Results: PET/CT was positive in 96.6% of patients and revealed that 13.8% of patients had locally recurrent disease, 58.6% had isolated lymph node metastases, 20.7% had isolated bone metastases, and 3.4% showed lymph node metastases and a vertebral metastasis. The median follow-up was 8.3 months (range 3.0–17.3 months). The median PSA prior to radiotherapy was 1.47 ng/ml (range 0.52–32.01 ng/ml) and showed a statistically significant decrease to 0.58 ng/ml (range <0.07 to 6.33 ng/ml, p <0.001). Two patients (6.8%) developed progressive disease outside the radiation field after 12.0 and 12.7 months, yielding a local control rate of 100% at the median follow-up. No grade III acute toxicity or late toxicity grade II was observed. Only 2 patients (6.8%) reported persisting grade I diarrhoea according to the LENT-SOMA criteria 3 months after radiotherapy. Deterioration of the urinary or faecal continence was not observed. Conclusion: Preliminary results in the presented cohort suggest that radiotherapy based on 68Ga-PSMA ligand PET/CT yields effective local control and significant treatment response in terms of PSA levels in the absence of clinically important side effects. Furthermore, this approach delayed the necessity of androgen deprivation therapy or systemic therapy.

Translated title of the contribution68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy
Original languageGerman
Pages (from-to)1-9
Number of pages9
JournalStrahlentherapie und Onkologie
DOIs
StateAccepted/In press - Jun 7 2016
Externally publishedYes

Keywords

  • Androgen deprivation therapy
  • Local control
  • Neoplasm recurrence, local
  • Prostate-specific antigen
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Fingerprint

Dive into the research topics of '<sup>68</sup>Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy'. Together they form a unique fingerprint.

Cite this